In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other ...

Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate ...

Inc.’s stock price changed recently Upgrades and downgrades for EWTX from analysts EWTX’s stock price momentum as measured by ...

Cytokinetics (CYTK) stock rises and rival Edgewise (EWTX) stock drops as the latter posts mixed Phase 2 trial data for its heart disorder therapy EDG-7500. Read more here.

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other stocks that insiders bought in April after Trump’s tariff rollout.

Edgewise Therapeutics shares are trading lower by 25.7% during Wednesday's session. The company announced an approximate $200 million offering.

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX stock update.

Piper Sandler reaffirmed their overweight rating on shares of Edgewise Therapeutics (NASDAQ:EWTX – Free Report) in a research ...

Edgewise Therapeutics (EWTX) announced top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive ...

Below is a chart showing SOC's trailing twelve month trading history, with the $15 strike highlighted in orange: Edgewise Therapeutics Inc (Symbol: EWTX) saw options trading volume of 7,570 ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other unstoppable stocks that could double your money. Generating significant returns ...

Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate, EDG-7500, in patients with obstructive or nonobstructive hypertrophic ...